12 Stocks with 100%+ Upside Potential

NASDAQ: AUPH | Aurinia Pharmaceuticals Inc News, Ratings, and Charts

AUPH – This a truly unique list of stocks. That’s because each has at least 100% upside potential to the average target price set by Wall Street Analysts.

This a truly unique list of stocks. That’s because each has at least 100% upside potential to the average target price set by Wall Street Analysts. 

What needs to be pointed out is that most analysts are not big time risk takers. It is often better to keep a low profile than make outrageous predictions that don’t come true. That’s a path towards getting fired. 

This “take it safe” attitude certainly comes into play when we are talking about target prices. The vast majority of the time they are only 10-20% above current levels. That is true even if they think the stock has more upside potential. Their game plan will be to just raise the target as the stock approaches their original target. 

So what would cause an analyst to have a target price that is a full 100% higher? 

The obvious answer is that they are BEYOND convinced that the stock is undervalued and has incredibly high odds of ascending to these levels. And in this case, we are not talking about 1 analyst going out on a limb…but the average of all analysts following the stock. 

Yes, it is fair to say the more analysts, the merrier!  

Note that this stock search started with over 8,000 stocks to screen from. From there we only applied 2 parameters that quickly boiled things down to these 12 extraordinary stocks. 

Yes, all the stocks are small caps. And yes, they are all under $10. But still the fact remains that they are loaded with positive qualities that greatly increase their odds of outperformance. 

The one last thing about this list. These are SPECULATIVE stocks. 

Do not own too many of them…and don’t put too much in any singular pick unless you can stomach the risk that comes along from super volatile small cap stocks. But if you play your cards right, few stocks will have as explosive of upside potential. Long story short, be sure to balance out the risk and reward.

Here are all 12 stocks that meet the unique criteria shared above: 

Company Ticker Market Cap ($mil) Price Avg. Target Price Upside %
Anavex Life Sci AVXL $166  $3.21  $10.00  211.53%
Brainstorm Cell BCLI $94  $4.31  $12.67  193.97%
Agile Therap AGRX $61  $1.40  $4.00  185.71%
Aurinia Pharma AUPH $586  $6.39  $17.17  168.70%
Veru Inc VERU $148  $2.36  $5.88  149.15%
Vista Gold Corp VGZ $79  $0.79  $1.95  146.84%
Lithium Americs LAC $355  $3.99  $9.57  139.85%
Aptose Biosci APTO $154  $2.77  $6.50  134.66%
Compugen Ltd CGEN $184  $3.58  $8.00  123.46%
Novan Inc NOVN $75  $2.87  $6.00  109.06%
Celsius Holding CELH $250  $4.36  $8.75  100.69%
Syndax Pharma SNDX $240  $8.87  $17.80  100.68%

 

Also here are links to 3 other popular destinations to make the best use of the POWR Ratings:

Full List of “A ”Rated Strong Buy Stocks–  See all the top rated stocks. 

About the POWR Ratings Learn what’s build inside the POWR Ratings that helps find stocks ready to outperform. 

Reitmeister Total Return portfolio. This is where Steve Reitmeister employs his 40 years of investment experience to hand select the best POWR Ratings stocks. 

 

About the Author

Steve Reitmeister is the CEO of the Stock News Network bringing 40 years of experience to help individual investors find outperformance. For the better part of the past two decades he was the Editor-in-Chief of Zacks.com where millions of investors enjoyed his timely market insights. His commentary has also been featured on other leading investment websites including Yahoo Finance, SeekingAlpha, CNNMoney and MarketWatch. Steve has an MBA from DePaul University and B.A. in Economics from the University of Wisconsin (Go Badgers!).

 


AUPH shares were unchanged in after-hours trading Monday. Year-to-date, AUPH has declined -7.18%, versus a 21.46% rise in the benchmark S&P 500 index during the same period.


This article is brought to you courtesy of StockNews.

More Resources for the Stocks in this Article

TickerPOWR RatingIndustry RankRank in Industry
AUPHGet RatingGet RatingGet Rating
Get RatingGet RatingGet Rating
Get RatingGet RatingGet Rating
Get RatingGet RatingGet Rating
Get RatingGet RatingGet Rating

Most Popular Stories on StockNews.com


Updated 2024 Stock Market Outlook

The bull market continues to rage on with the S&P 500 (SPY) making new highs. That is the past...the question is what does the future hold? That is why 44 year investment veteran Steve Reitmeister provides this updated 2024 Stock Market Outlook to help you carve a path to outperformance the rest of the year. Read on below for the full story...

Top 4 Tech Giants Poised for Explosive Growth

Fueled by the ever-growing demand for advanced technological solutions across various sectors and ongoing innovation, the tech industry has robust growth prospects. Thus, it could be wise to invest in top tech stocks Dropbox (DBX), TTM Technologies (TTMI), Lantronix (LTRX) and AstroNova (ALOT) for potential growth. Continue reading…

3 Top Rated Software Stocks to Streamline Your Investments

The software industry is thriving with soaring demand, presenting ample investment opportunities. So, fundamentally solid software stocks ServiceNow (NOW), Autodesk (ADSK), and Docebo (DCBO) might be ideal buys for promising returns. Read on...

Biotech Investors: Should You Buy, Hold, or Sell Moderna (MRNA) and Arrowhead Pharmaceuticals (ARWR)?

Despite facing several challenges, the biotech sector thrives due to growing demand for effective treatments, consistent innovations, and a sustained demand for high-quality drugs and therapies. Let's assess whether one should Buy, Hold, or Sell biotech stocks Moderna (MRNA) and Arrowhead Pharmaceuticals (ARWR). Keep reading...

Investor Alert: “Buy the Rumor, Sell the News!”

Everyone knows that the Fed is going to cut rates at some point this year. That is the worst kept secret on the planet helping to explain how we keep making new highs for the for the S&P 500 (SPY). Unfortunately that creates an interesting predicament for stocks after rates are cut. Plus another hurdle in the 2024 Presidential election. Steve Reitmeister is here to share his insights on the market outlook along with a preview of his top 12 stocks to outperform. Read on for more...

Read More Stories

More Aurinia Pharmaceuticals Inc (AUPH) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All AUPH News